Core Insights - Anixa Biosciences, Inc. is participating in the Water Tower Research Fireside Chat Series on December 15, 2025, with CEO Dr. Amit Kumar as a speaker [1][2] - The company focuses on cancer treatment and prevention, with a notable emphasis on ovarian cancer immunotherapy and vaccine development [2] Company Overview - Anixa is a clinical-stage biotechnology company specializing in cancer treatment and prevention [2] - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers like lung, colon, and prostate [2] - The vaccines target "retired" proteins expressed in certain cancers, with exclusive licensing agreements in place with Cleveland Clinic for breast and ovarian cancer vaccines [2] Upcoming Events - The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and is open to all investors [2] - Final data from Anixa's Phase 1 breast cancer vaccine trial will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium [5]

Core Insights - FibroBiologics has submitted a new patent application for a fibroblast-derived therapy platform aimed at orthopedic and musculoskeletal conditions, which includes degenerative disc repair and cartilage repair [1][2][3] - The application, if granted, will enhance the protection of the company's innovative fibroblast technology, which has shown promise in preclinical studies for integrating with native tissue and promoting regeneration [2][3] - The CEO of FibroBiologics emphasized that this patent application is a significant advancement in expanding the company's focus from chronic wounds to the structural repair of the musculoskeletal system, targeting large markets in degenerative disc disease and joint disease [3] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, specializing in developing treatments and potential cures for chronic diseases using fibroblast cells and materials [4] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and orthopedics [4] - FibroBiologics aims to be at the forefront of medical advancements in cell therapy and tissue regeneration [4]

Core Insights - PharmAla Biotech Holdings Inc. has successfully completed the release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules, marking a significant milestone for the company [1] - The company is set to enter an active production schedule for 2026, which includes the development of 20mg capsules and the manufacture of ALA-002 capsules [2] - PharmAla has completed its first delivery of Australian-made product to the Orygen Institute, supporting a Phase 3 Trial for social anxiety in autistic youth, concluding its contract with Orygen [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for clinical trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates, including ALA-002 [4] - PharmAla operates under a "regulatory first" principle, emphasizing the importance of strong relationships with regulators in the psychedelics industry [4]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company specializes in medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - BigBear.ai has announced a partnership with Vigilix, indicating a strategic foothold in the Middle East [1] - The company is focused on leveraging its technological capabilities to enhance its market presence in the region [1] Group 2 - The article emphasizes the importance of evaluating the science behind drug candidates and the competitive landscape in the biotech sector [1] - It highlights the potential for breakthrough science to lead to significant returns, while also noting the necessity for careful scrutiny in investment decisions [1]

Core Insights - BriaCell Therapeutics Corp. presented positive Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium, highlighting the potential of its Bria-IMT regimen in treating metastatic breast cancer [1][6]. Group 1: Clinical Data and Findings - The Bria-IMT regimen shows promise in addressing unmet needs in metastatic breast cancer treatment, particularly for patients with CNS metastasis who have undergone a median of 6 prior treatments [2][6]. - The Phase 3 study involves a randomized trial comparing Bria-IMT plus immune checkpoint inhibitors, Bria-IMT monotherapy, and Treatment of Physician's Choice, with a focus on safety, biomarker correlations, and progression-free survival (PFS) [4][6]. - The regimen demonstrated a favorable safety profile with no treatment-related discontinuations due to adverse events, and the most common adverse events were low grade [7]. Group 2: Biomarker Insights - Neutrophil-to-Lymphocyte Ratio (NLR) emerged as a potential predictive biomarker, with patients showing favorable NLR (0.7 – 2.3) experiencing longer PFS (4.4 months) compared to those with NLR <0.7 or >2.3 (2.6 months) [7][8]. - Positive Delayed Type Hypersensitivity (DTH) was identified as a key predictor of clinical benefit, with median overall survival significantly higher in DTH+ patients (11.3 months) compared to DTH- patients (4.7 months) [10][11]. - Th1-biased cytokines and chemokines may serve as potential predictive biomarkers for clinical responses to the Bria-IMT regimen, indicating enhanced T-cell activation and pro-inflammatory signaling [16][14]. Group 3: Future Directions - Further evaluation of cytokine and chemokine biomarkers is planned to establish more personalized therapeutic strategies for metastatic breast cancer patients with limited treatment options [3][11]. - Ongoing analysis will continue as enrollment progresses and overall survival data matures, reinforcing the potential clinical benefits of the Bria-IMT regimen [8][11].

Core Insights - ProMIS Neurosciences Inc. is advancing its lead product candidate PMN310, a humanized monoclonal antibody designed to selectively target toxic oligomers associated with Alzheimer's disease (AD), potentially improving clinical outcomes and quality of life for patients and caregivers [3][10] - The ongoing PRECISE-AD trial is expected to complete enrollment by the end of 2025, with interim results anticipated in Q2 2026 and top-line results in Q4 2026 [1][11] Group 1: Key Findings and Implications - The study published in Alzheimer's & Dementia highlights the importance of selectively targeting soluble toxic Aβ aggregates, showing a correlation between selectivity for these oligomers and clinical efficacy [2][4] - PMN310 demonstrated the highest resistance to monomer competition among tested antibodies, preserving oligomer binding, which may translate into clinical benefits for patients [6][13] Group 2: Safety and Efficacy - PMN310's lack of binding to plaque or vascular deposits suggests a potentially lower risk of amyloid-related imaging abnormalities (ARIA), a common side effect of current anti-amyloid therapies [5][10] - Preclinical studies indicated that high-dose chronic administration of PMN310 did not produce microhemorrhages in plaque-bearing mice, supporting the hypothesis of reduced ARIA risk [6][10] Group 3: Clinical Trial Design - The PRECISE-AD trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD, with a targeted enrollment of 128 patients [11] - This trial will be the first to examine the effects of a monoclonal antibody directed solely against toxic amyloid-beta oligomers on biomarkers associated with AD pathology and clinical outcomes [11][13]

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].

As filed with the Securities and Exchange Commission on December 9, 2025. Registration No. 333-291999 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 82-4369909 (I.R.S. Employer Identification Number) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 (619) 400-117 ...

Core Insights - Voyager Technologies reported a 3Q25 Non-GAAP EPS of -$0.22, exceeding expectations by approximately $0.09 [1] - Revenue for the quarter was $39.6 million, slightly below consensus estimates by $0.94 million [1] Financial Performance - The Non-GAAP EPS of -$0.22 indicates a loss, but it is an improvement compared to market expectations [1] - The revenue figure of $39.6 million reflects a minor shortfall against analyst consensus, suggesting potential challenges in revenue generation [1]